<DOC>
	<DOCNO>NCT00423527</DOCNO>
	<brief_summary>Multiple sclerosis often associate pain . There standard treatment type pain . Levetiracetam new anticonvulsant hypothesis could relieve central pain multiple sclerosis . This randomised , double-blind , placebo-controlled , cross-over trial effect levetiracetam 3000 mg daily pain multiple sclerosis .</brief_summary>
	<brief_title>Levetiracetam Central Pain Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>ms diagnosis verify age &gt; 18 year central pain symptom 3 month central pain diagnosis confirm neurological examination adequate anticonceptive treatment woman child bear potential inform consent baseline pain 4 numeric rating scale cause pain previous allergic reaction towards levetiracetam know adverse drug reaction levetiracetam pregnancy severe disease inability follow study protocol treatment antidepressant , anticonvulsant opioids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>central pain</keyword>
	<keyword>levetiracetam</keyword>
</DOC>